Pfizer's BRAFTOVI shows promise in colorectal cancer trial
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...
STAT7d
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pfizer’s Braftovi improves survival in Phase 3 colorectal cancer trial
Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FiercePharma3d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Pfizer: BRAFTOVI Combination Regimen Shows Significant Improvement In PFS In Phase 3 Trial In MCRC
Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...
JD Supra3d
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
The Pharma Letter7d
Positive Phase III results for Pfizer’s Braftovi combo
US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...
PLX: Revisiting the Thesis
PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) ...
appliedclinicaltrialsonline5d
Pfizer Shares Positive Data from Phase III BREAKWATER Trial of Braftovi Combination Following Accelerated Approval
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
dermatologyadvisor2d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
AOL3d
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...